Comparative Pharmacology
Head-to-head clinical analysis: SEROSTIM LQ versus SOGROYA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SEROSTIM LQ versus SOGROYA.
SEROSTIM LQ vs SOGROYA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Recombinant human growth hormone (somatropin) that binds to growth hormone receptors, activating JAK-STAT signaling pathways, leading to increased insulin-like growth factor-1 (IGF-1) production, which promotes linear growth and anabolic effects.
Selective progesterone receptor modulator (SPRM) with antiproliferative and proapoptotic effects on endometrial tissue, and suppression of ovulation.
0.2 mg/kg subcutaneously once daily for 4 weeks in HIV-associated wasting; for growth hormone deficiency, 0.005 mg/kg subcutaneously once daily initially, titrated to 0.01 mg/kg once daily.
Subcutaneous injection: 10 mg once daily for 6 days, followed by 30 mg once daily thereafter.
None Documented
None Documented
2.6 hours (subcutaneous administration); terminal half-life is approximately 2-3 hours, requiring daily dosing for growth hormone deficiency.
Terminal elimination half-life is approximately 2.5-3 hours in healthy adults. In patients with renal impairment, half-life is prolonged (up to 10-15 hours in end-stage renal disease).
Renal: >90% of somatropin is metabolized in the liver and kidneys; less than 1% of the administered dose is excreted unchanged in urine.
Primarily renal (hepatic metabolism and biliary excretion are minor). Approximately 70-80% of a dose is excreted unchanged in urine via glomerular filtration and tubular secretion. Fecal excretion accounts for <20%.
Category C
Category C
Growth Hormone
Growth Hormone